Systemic Sclerosis – Actual perspectives

Detalhes bibliográficos
Autor(a) principal: Vilas, Ana Paula
Data de Publicação: 2002
Outros Autores: Veiga, Manuela Zita, Abecasis, Pedro
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://revista.spmi.pt/index.php/rpmi/article/view/1939
Resumo: ystemic sclerosis is a relatively rare disease, characterized by variable degrees of fibrosis within the skin and internal organs. There are two major subsets, limited and diffuse systemic sclerosis, which are differentiated primarily by the extent of skin involvement, and are characterized by different disease evolution and prognosis. Concepts regarding this disease have changed over the years. Uniform concepts are extremely important, as they will allow comparison of groups of patients from different centres, and therefore facilitate a better knowledge of this disease.Although systemic sclerosis was first described in the 18th century and is recognized as a multi-systemic disease since the 19th century (before, cutaneous sclerosis – scleroderma – was considered as one disease and other diseases, such as gastrointestinal, pulmonary, etc., were considered to be associated with it), its’ aetiology remains unknown and its’ pathogenesis not entirely understood. This has resulted in the non-existence of a specific and therefore curative treatment. Despite this, advances have been made regarding the treatment of several of the disease manifestations. The discovery that angiotensin-converting enzyme (ACE) inhibitors, for instance are effective in the treatment of sclero-derma renal crisis, the most fatal complication of systemic sclerosis up till then. Such new advances have allowed improvement in the quality of life and the rate of survival of these patients. In this article, the new perspectives of treatment of this disease and its’ different aspects are discussed.
id RCAP_1edae1c6a4dd8b1b9df85508678a6a9e
oai_identifier_str oai:oai.revista.spmi.pt:article/1939
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Systemic Sclerosis – Actual perspectivesEsclerose sistémica - perspectivas actuaisEsclerose sistémicaclassificaçãodiagnósticotratamentoprognósticoesclerodermiaSystemic sclerosissclerodermaclassificationdiagnosistreatmentprognosisystemic sclerosis is a relatively rare disease, characterized by variable degrees of fibrosis within the skin and internal organs. There are two major subsets, limited and diffuse systemic sclerosis, which are differentiated primarily by the extent of skin involvement, and are characterized by different disease evolution and prognosis. Concepts regarding this disease have changed over the years. Uniform concepts are extremely important, as they will allow comparison of groups of patients from different centres, and therefore facilitate a better knowledge of this disease.Although systemic sclerosis was first described in the 18th century and is recognized as a multi-systemic disease since the 19th century (before, cutaneous sclerosis – scleroderma – was considered as one disease and other diseases, such as gastrointestinal, pulmonary, etc., were considered to be associated with it), its’ aetiology remains unknown and its’ pathogenesis not entirely understood. This has resulted in the non-existence of a specific and therefore curative treatment. Despite this, advances have been made regarding the treatment of several of the disease manifestations. The discovery that angiotensin-converting enzyme (ACE) inhibitors, for instance are effective in the treatment of sclero-derma renal crisis, the most fatal complication of systemic sclerosis up till then. Such new advances have allowed improvement in the quality of life and the rate of survival of these patients. In this article, the new perspectives of treatment of this disease and its’ different aspects are discussed.A esclerose sistémica (ES) é uma doença relativamente rara, caracterizada por diferentes graus de fibrose da pele e dos órgãos internos. Pode ser dividida em dois grupos principais: ES limitada e ES difusa. Estes diferenciam-se, sobretudo, pela extensão do envolvimento cutâneo e caracterizam-se por evoluções e prognósticos diferentes. Ao longo dos anos ocorreram várias alterações a nível de conceitos relacionados com a ES. A uniformização destes é de grande importância, já que permite a realização de estudos em que se comparam grupos de doentes de centros diferentes, facilitando assim o melhor conhecimento desta entidade patológica. Apesar de a ES ser conhecida desde o século XVIII e ser reconhecida como patologia multissistémica desde o século XIX (antes considerava-se a esclerose cutânea – esclerodermia – como uma entidade patológica, a que se associavam outras doenças gastrointestinais, pulmonares, etc.), a sua etiologia continua a ser desconhecida e a sua patogénese não totalmente esclarecida. Isto leva a que não exista um tratamento específico e, portanto, curativo. Apesar disso, hoje já é possível controlar muitas das manifestações da ES. O aparecimento dos inibidores do enzima de conversão da angiotensina (IECA) na década de oitenta, por exemplo, permitiu controlar aquela que era até então a maior causa de morte na ES, a crise renal esclerodérmica. Este e outros novos avanços têm permitido melhorar a qualidade de vida destes doentes, bem como a sua esperança de vida. Neste trabalho abordam-se as perspectivas actuais de tratamento desta patologia e dos seus diferentes aspectos.Sociedade Portuguesa de Medicina Interna2002-06-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spmi.pt/index.php/rpmi/article/view/1939Internal Medicine; Vol. 9 No. 2 (2002): Abril/ Junho; 111-120Medicina Interna; Vol. 9 N.º 2 (2002): Abril/ Junho; 111-1202183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/1939https://revista.spmi.pt/index.php/rpmi/article/view/1939/1355Vilas, Ana PaulaVeiga, Manuela ZitaAbecasis, Pedroinfo:eu-repo/semantics/openAccess2023-05-27T06:11:02Zoai:oai.revista.spmi.pt:article/1939Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:56:25.339551Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Systemic Sclerosis – Actual perspectives
Esclerose sistémica - perspectivas actuais
title Systemic Sclerosis – Actual perspectives
spellingShingle Systemic Sclerosis – Actual perspectives
Vilas, Ana Paula
Esclerose sistémica
classificação
diagnóstico
tratamento
prognóstico
esclerodermia
Systemic sclerosis
scleroderma
classification
diagnosis
treatment
prognosis
title_short Systemic Sclerosis – Actual perspectives
title_full Systemic Sclerosis – Actual perspectives
title_fullStr Systemic Sclerosis – Actual perspectives
title_full_unstemmed Systemic Sclerosis – Actual perspectives
title_sort Systemic Sclerosis – Actual perspectives
author Vilas, Ana Paula
author_facet Vilas, Ana Paula
Veiga, Manuela Zita
Abecasis, Pedro
author_role author
author2 Veiga, Manuela Zita
Abecasis, Pedro
author2_role author
author
dc.contributor.author.fl_str_mv Vilas, Ana Paula
Veiga, Manuela Zita
Abecasis, Pedro
dc.subject.por.fl_str_mv Esclerose sistémica
classificação
diagnóstico
tratamento
prognóstico
esclerodermia
Systemic sclerosis
scleroderma
classification
diagnosis
treatment
prognosis
topic Esclerose sistémica
classificação
diagnóstico
tratamento
prognóstico
esclerodermia
Systemic sclerosis
scleroderma
classification
diagnosis
treatment
prognosis
description ystemic sclerosis is a relatively rare disease, characterized by variable degrees of fibrosis within the skin and internal organs. There are two major subsets, limited and diffuse systemic sclerosis, which are differentiated primarily by the extent of skin involvement, and are characterized by different disease evolution and prognosis. Concepts regarding this disease have changed over the years. Uniform concepts are extremely important, as they will allow comparison of groups of patients from different centres, and therefore facilitate a better knowledge of this disease.Although systemic sclerosis was first described in the 18th century and is recognized as a multi-systemic disease since the 19th century (before, cutaneous sclerosis – scleroderma – was considered as one disease and other diseases, such as gastrointestinal, pulmonary, etc., were considered to be associated with it), its’ aetiology remains unknown and its’ pathogenesis not entirely understood. This has resulted in the non-existence of a specific and therefore curative treatment. Despite this, advances have been made regarding the treatment of several of the disease manifestations. The discovery that angiotensin-converting enzyme (ACE) inhibitors, for instance are effective in the treatment of sclero-derma renal crisis, the most fatal complication of systemic sclerosis up till then. Such new advances have allowed improvement in the quality of life and the rate of survival of these patients. In this article, the new perspectives of treatment of this disease and its’ different aspects are discussed.
publishDate 2002
dc.date.none.fl_str_mv 2002-06-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/1939
url https://revista.spmi.pt/index.php/rpmi/article/view/1939
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/1939
https://revista.spmi.pt/index.php/rpmi/article/view/1939/1355
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.source.none.fl_str_mv Internal Medicine; Vol. 9 No. 2 (2002): Abril/ Junho; 111-120
Medicina Interna; Vol. 9 N.º 2 (2002): Abril/ Junho; 111-120
2183-9980
0872-671X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131638969401344